Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Guillermo Garcia-Manero, Lucia Masarova, Koji Sasaki, Nitin Jain, Prithviraj Bose, Hagop M. Kantarjian, Elias Jabbour, Steven M. Kornblau, Nicholas J. Short, Sherry Pierce, Farhad Ravandi, Naval Daver, Musa Yilmaz, Abhishek Maiti, Marina Konopleva, Ghayas C. Issa, Naveen Pemmaraju, Philip A. Thompson, Koichi Takahashi, Tapan M. Kadia, Michael Andreeff, Alessandra Ferrajoli, Caitlin R. Rausch, Yesid Alvarado, Courtney D. DiNardo, Maro Ohanian, Wei Qiao, Kiran Naqvi, Kathryn S. Montalbano, Gautam Borthakur, Jing Ning
Publikováno v:
Am J Hematol
Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are "fit" or "unfit" for
Autor:
Naval Daver, Zeev Estrov, Qiao Wei, Elias Jabbour, Simon Abi Aad, Farhad Ravandi, Simona Colla, Paolo Strati, Yue Wei, Guillermo Garcia-Manero, Susan O'Brien, Courtney D. DiNardo, Tapan M. Kadia, Jianhua Hu, Monica Cabrero, Gautam Borthakur, William G. Wierda, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Jorge E. Cortes, Nicholas J. Short
Publikováno v:
American Journal of Hematology. 92:351-358
Two hundred and sixteen consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12 were reviewed. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 7
Autor:
Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortes, Sherry Pierce, Guillermo Garcia-Manero, Naveen Pemmaraju, Nitin Jain, Tapan M. Kadia, Elias Jabbour, Jeffrey L. Jorgensen, Deborah A. Thomas, Sa A. Wang, Sergej Konoplev, Xuemei Wang, Susan O'Brien, Xuelin Huang, Rebecca Garris
Publikováno v:
American Journal of Hematology. 92:279-285
We sought to determine the significance of minimal residual disease (MRD) relapse in patients with ALL after achieving MRD negative status following induction and consolidation therapy. Between January 2003 and September 2014, 647 newly diagnosed pat
Autor:
Farhad Ravandi, Sherry Pierce, Susan O'Brien, Guillermo Garcia-Manero, Rebecca Garris, Sa Wang, Naveen Pemmaraju, Michael Rytting, Elias Jabbour, Steven M. Kornblau, Anna Franklin, Deborah A. Thomas, Gautam Borthakur, Hagop M. Kantarjian, Jorge E. Cortes, Alessandra Ferrajoli, Jeffrey L. Jorgensen, Marina Konopleva, Kurt Schroeder, Naval Daver, Tapan M. Kadia
Publikováno v:
American Journal of Hematology. 91:819-823
Several studies reported improved outcomes of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated with pediatric-based ALL regimens. This prompted the prospective investigation of a pediatric Augmented Berlin-Frankfurt-
Autor:
Sangbum Choi, Michael Andreeff, Aziz Nazha, Steve Kornblau, Gautam Borthakur, Hagop M. Kantarjian, Jorge E. Cortes, Alessandra Ferrajoli, Zeev Estrov, Farhad Ravandi, Naval Daver, Elias Jabbour, Mark Brandt, Tapan M. Kadia, Min Du, Stefan Faderl, Naveen Pemmaraju, Marina Konopleva, Guillermo Garcia-Manero, Xuelin Huang
Publikováno v:
American Journal of Hematology. 88:961-966
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin, and cytarabine (CIA) in relapsed and refractory AML had shown an overall response rate (ORR)
Autor:
Mark Brandt, Hagop M. Kantarjian, Hsiang Chun Chen, Jorge E. Cortes, Peng Qiu, Nicholas J. Short, Sherry Pierce, Kiran Naqvi, Farhad Ravandi, Abhishek Maiti, Guillermo Garcia-Manero, Lisa Gu, Taejin L. Min, Alfonso Quintás-Cardama, Christopher B. Benton, Tapan M. Kadia, Michael Andreeff, Marina Konopleva, Elias Jabbour
Publikováno v:
American journal of hematology. 91(12)
In patients with acute myeloid leukemia (AML), rapid reduction of circulating blasts with induction chemotherapy may serve as an in vivo marker of chemosensitivity. We performed a retrospective analysis of 363 patients with untreated AML who received
Autor:
Talha, Badar, Hagop M, Kantarjian, Graciela M, Nogueras-Gonzalez, Gautam, Borthakur, Guillermo, Garcia Manero, Michael, Andreeff, Marina, Konopleva, Tapan M, Kadia, Naval, Daver, William G, Wierda, Raja, Luthra, Keyur, Patel, Betul, Oran, Richard, Champlin, Farhad, Ravandi, Jorge E, Cortes
Publikováno v:
American journal of hematology. 90(11)
AML with FLT3 ITD mutations are associated with poor outcome. We reviewed outcomes of patients with FLT3 ITD mutated AML to investigate trends over time. We analyzed 224 AML patients (excluding patients with core binding factor and acute promyelocyti